NET PROFIT FORECAST: Takeda's net profit is expected to have declined 0.4% from a year earlier to 94.89 billion yen, equivalent to $642.6 million, for the three months ended June 30, according to a ...

Takeda offers strong cash flow, solid growth in key areas, and a 4.4% yield, but trades at a premium despite its fundamentals. Read why TAK stock is a hold.

Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controlled studies of oveporexton (TAK-861), a potential ...

Takeda is on track to submit its much-hyped narcolepsy drug to regulators this fiscal year after the orexin receptor 2 (OX2R) ...

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK) shares rose 3.5% following the announcement of encouraging Phase 3 trial results for its investigational narcolepsy treatment, oveporexton. The Japanese ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Positive late-stage study results position the company to file for clearance of what could be the first narcolepsy drug that ...

Takeda’s oveporexton improved wakefulness, attention and other key narcolepsy endpoints “with a high degree of statistical ...

The positive results are a major leap forward for Takeda's orexin programme, which looked in jeopardy in 2021 when lead asset TAK-994 was abandoned after phase 2 trials in type 1 and type 2 narcolepsy ...

Takeda now projects that its net profit for the fiscal year ending March 2024 will drop 71% to ¥93.00 billion By Kosaku Narioka Updated Oct. 26, 2023 4:44 am ET Share ...

Costa Saroukos, who became Takeda’s global finance chief in 2018, discusses why moving fast after an acquisition is crucial in melding company cultures and cutting back debt.